Cepeloron

AuthorisedVeterinary

Details

EMA number

EMEA/V/C/006254

EMA page

Therapeutic indication

Not specified

Active substances

spironolactone

🇺🇸 Also approved in the US (FDA)

SPIRONOLACTONE — CMP DEV LLC, approved 2023-08-24 (NDA209478).

Most reported adverse events (US / FAERS)

96,567 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

dyspnoea

10,689

fatigue

8,426

nausea

8,049

diarrhoea

7,642

acute kidney injury

🇺🇸 Also approved in the US (FDA)

SPIRONOLACTONE — CMP DEV LLC, approved 2023-08-24 (NDA209478).

Most reported adverse events (US / FAERS)

96,567 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

dyspnoea

10,689

fatigue

8,426

nausea

8,049

diarrhoea

7,642

acute kidney injury

6,906

dizziness

6,418

headache

6,077

hypotension

5,932

off label use

5,800

drug ineffective

5,332

fall

5,199

asthenia

5,108

death

5,023

hyperkalaemia

4,988

vomiting

4,978